Intratumoral injection of anti-CTLA4 antibodies in a slow-release formulation with an eight-fold lower dose of antibodies achieved tumor eradication as systemic delivery and resulted in thousand-fold decreased levels of antibodies in the serum, reducing adverse events and the risk of autoimmunity [83]. Here, CTLA4 is linked to neoplasm.